Ivermectin a drug of indiscriminate use in the management of Covid-19
Abstract
The Coronaviridae are a family of RNA viruses that have affected mammals and birds throughout history. These pathogens, known and studied for several decades, have also been responsible for infections that usually occur in the respiratory tract in humans. Its most recent variant SARS-CoV-2, was identified at the end of 2019 in the Chinese city of Wuhan where the virus was identified as the cause of multiple severe pneumonia in the population (1).
This outbreak had an extension that exceeded expectations, creating the largest milestone of the 21st century. On March 11, 2020, the virus was declared a pandemic, its direct transmission from person to person played a very important role in the rapid spread of this new coronavirus. Its wide range of clinical presentation, ranging from completely asymptomatic forms to reaching more serious and even fatal respiratory tract infections, never seen before (2), became a social, political and medical challenge.
References
Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to- person transmission: a study of a family cluster. Lancet [Internet]. 2020;395(10223):514–23. doi: http://dx.doi.org/10.1016/S0140-6736(20)30154-9
Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med [Internet]. 2021;174(1):69–79. doi: https://doi.org/10.7326/M20-5008
ZemkovaH,TvrdonovaV,BhattacharyaA,Jindrichova M. Allosteric modulation of ligand gated ion channels by ivermectin. Vol. 63, Physiological Research. 2014. doi: https://doi.org/10.33549/physiolres.932711
Banerjee K, Nandy M, Dalai CK, Ahmed SN. The Battle against COVID 19 Pandemic: What we Need to Know Before we “Test Fire” Ivermectin. Drug Res (Stuttg). 2020;70(8):337-340. doi: https://doi.org/10.1055/a-1185-8913
Instituto Nacional de Vigilancia de Medicamentos y Alimentos - INVIMA. Sistema de Trámites en Línea - Consultas Públicas. 2017. :8082. Available from: http://consultaregistro.invima.gov.co:8082/Consultas/consultas/consreg_encabcum.jsp
Schmith VD, Zhou J, Lohmer LRL. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther [Internet]. 2020;108(4):762–5. doi: https://doi.org/10.1002/cpt.1889
Caly L, Druce JD, Catton MG, Jans DA, Wagsta KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research 178, 104787. Antiviral Res [Internet]. 2020;178(January):104787. doi: https://doi.org/10.1016/j.antiviral.2020.104787
Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. ICON (Ivermectin in Covid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. medRxiv [Internet]. 2020;(January). doi: https://doi.org/10.1101/2020.06.06.20124461
Ortega-Guillén E, Meneses G, Coila E. Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study). CHEST J [Internet]. 2020;159(1):2110–1. doi: https://doi.org/10.1016/j.chest.2020.10.088
Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214– 6. doi: https://doi.org/10.1016/j.ijid.2020.11.191
Camprubí D, Almuedo-Riera A, Martí-Soler HI, Soriano A, Hurtado JC, Subirà C, et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS One. 2020;15(11 November):1–6. doi: https://doi.org/10.1371/journal.pone.0242184
Behera P, Patro BK, Singh AK, Chandanshive PD, Ravikumar SR, Pradhan SK, et al. Role of ivermectin in the prevention of SARSCoV-2 infection among healthcare workers in India: A matched case-control study. PLoS One [Internet]. 2021;16(2 February):1–12. Available from: http://dx.doi.org/10.1371/journal.pone.0247163
López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 A Randomized Clinical Trial Visual Abstract Supplemental content. JAMA [Internet]. 2021;325(14):1426–35. Available from: https://jamanetwork.com/
Buonfrate D, Bisoffi Z. Standard Dose Ivermectin for COVID-19. Chest [Internet]. 2021;159(5):2111–2. doi: https://doi.org/10.1016/j.chest.2021.03.003
Zangrillo A. COVID-19 y Argumentum ad ignorantiam o «no todo vale». Rev Clínica Española [Internet]. 2020;10(January):19–21. doi: https://doi.org/10.1016/j.rce.2020.04.013
Downloads
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
